Gene screen predicts brain tumour prognosis:
This article was originally published in Clinica
Executive Summary
A team of researchers in Massachusetts, US, has developed a classification system of gene expression profiles that could help predict the clinical outcome of the most common type of childhood malignant brain tumour. Diagnosis of the condition, called medulloblastoma, on the basis of morphologic appearance alone is controversial and patient response to therapy is difficult to predict, according to a report published in Nature (January 24). The new DNA microarray gene expression-based system is highly predictive of outcome at the time of tumour diagnosis and may also shed light on why the tumours occur, said the team from the Massachusetts Institute of Technology, based in Cambridge.
You may also be interested in...
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip